Table of Content

"1    INTRODUCTION    27
1.1    OBJECTIVES OF THE STUDY    27
1.2    MARKET DEFINITION    27
1.2.1    INCLUSIONS & EXCLUSIONS OF THE STUDY    27
1.3    MARKET SCOPE    28
1.3.1    MARKETS COVERED    28
1.3.2    YEARS CONSIDERED FOR THE STUDY    29
1.3.3    CURRENCY    29
TABLE 1    EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD    29
1.4    STAKEHOLDERS    30
1.5    SUMMARY OF CHANGES    30
2    RESEARCH METHODOLOGY    32
2.1    RESEARCH DATA    32
FIGURE 1    RESEARCH DESIGN    32
2.1.1    SECONDARY DATA    33
2.1.1.1    Key data from secondary sources    34
2.1.2    PRIMARY DATA    34
FIGURE 2    PRIMARY SOURCES    34
2.1.2.1    Key data from primary sources    35
2.1.2.2    Key industry insights    36
FIGURE 3    BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION    36
FIGURE 4    BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS    37
2.2    MARKET SIZE ESTIMATION    37
FIGURE 5    SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS    38
FIGURE 6    REVENUE SHARE ANALYSIS ILLUSTRATION: SANOFI    38
FIGURE 7    REVENUE ANALYSIS OF THE TOP FOUR COMPANIES:
INJECTION PENS MARKET (2020)    39
FIGURE 8    CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTION
PENS MARKET (2021–2026)    40
FIGURE 9    CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS    41
FIGURE 10    TOP-DOWN APPROACH    41
2.3    MARKET BREAKDOWN & DATA TRIANGULATION    42
FIGURE 11    MARKET DATA TRIANGULATION METHODOLOGY    42
2.4    MARKET SHARE ANALYSIS    43
2.5    ASSUMPTIONS FOR THE STUDY    43

2.6    RISK ASSESSMENT    43
TABLE 2    RISK ASSESSMENT: INJECTION PENS MARKET    43
2.7    LIMITATIONS    44
2.7.1    METHODOLOGY-RELATED LIMITATIONS    44
2.7.2    SCOPE-RELATED LIMITATIONS    44
3    EXECUTIVE SUMMARY    45
FIGURE 12    INJECTION PENS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)    45
FIGURE 13    INJECTION PENS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)    46
FIGURE 14    INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2021 VS. 2026 (USD MILLION)    46
FIGURE 15    INJECTION PENS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)    47
FIGURE 16    GEOGRAPHICAL SNAPSHOT OF THE INJECTION PENS MARKET    48
4    PREMIUM INSIGHTS    49
4.1    INJECTION PENS MARKET OVERVIEW    49
FIGURE 17    GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH    49
4.2    ASIA PACIFIC: INJECTION PENS MARKET, BY THERAPY AND COUNTRY (2020)    50
FIGURE 18    DIABETES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC INJECTION PENS MARKET IN 2020    50
4.3    INJECTION PENS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES    51
FIGURE 19    CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE INJECTION PENS MARKET DURING THE FORECAST PERIOD    51
4.4    INJECTION PENS MARKET, BY REGION, 2021–2026    52
FIGURE 20    NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL
INJECTION PENS MARKET IN 2026    52
4.5    INJECTION PENS MARKET: DEVELOPED VS. DEVELOPING MARKETS    52
FIGURE 21    DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD    52
5    MARKET OVERVIEW    53
5.1    MARKET DYNAMICS    53
FIGURE 22    INJECTION PENS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES    53
5.1.1    MARKET DRIVERS    54
5.1.1.1    Growing prevalence of chronic diseases    54
FIGURE 23    NUMBER OF PEOPLE WITH CHRONIC DISEASES IN THE US,
1995–2030 (MILLION INDIVIDUALS)    54
FIGURE 24    ESTIMATED DIABETIC POPULATION, BY REGION,
2019 VS. 2030 VS. 2040 (MILLION)    55
FIGURE 25    GLOBAL CANCER INCIDENCE, 2015–2040 (MILLION)    55
5.1.1.2    Increasing number of regulatory approvals    55
5.1.1.3    Favorable reimbursement and government support    56
5.1.1.4    Technological advancements in injection pens    56
TABLE 3    MARKET DRIVERS: IMPACT ANALYSIS    57
5.1.2    MARKET RESTRAINTS    57
5.1.2.1    Preference for alternative drug delivery modes    57
5.1.2.2    Poor reimbursement scenario in developing countries    57
5.1.2.3    Needle anxiety    57
TABLE 4    MARKET RESTRAINTS: IMPACT ANALYSIS    58
5.1.3    MARKET OPPORTUNITIES    58
5.1.3.1    Patent expiry of biologics to drive the demand for biosimilars    58
5.1.3.2    Growth opportunities in emerging markets    58
FIGURE 26    DIABETES POPULATION IN DEVELOPING COUNTRIES,
2020 VS. 2040 (MILLION)    59
TABLE 5    RISING INCOME LEVELS IN EMERGING COUNTRIES    59
TABLE 6    MARKET OPPORTUNITIES: IMPACT ANALYSIS    60
5.1.4    MARKET CHALLENGES    60
5.1.4.1    Needlestick injuries and misuse of injection pens    60
TABLE 7    MARKET CHALLENGES: IMPACT ANALYSIS    61
5.2    VALUE CHAIN ANALYSIS    61
FIGURE 27    INJECTION PENS MARKET: VALUE CHAIN ANALYSIS    61
5.3    SUPPLY CHAIN ANALYSIS    62
FIGURE 28    INJECTION PENS MARKET: SUPPLY CHAIN ANALYSIS    63
5.4    PRICING ANALYSIS    63
TABLE 8    PRICING OF INJECTION PENS AVAILABLE IN THE MARKET    64
5.5    ECOSYSTEM MARKET MAP    65
FIGURE 29    INJECTION PENS MARKET: ECOSYSTEM MARKET MAP    65
5.6    PORTER’S FIVE FORCES ANALYSIS    65
TABLE 9    INJECTION PENS MARKET: PORTER’S FIVE FORCES ANALYSIS    65
5.6.1    INTENSITY OF COMPETITIVE RIVALRY    66
5.6.2    BARGAINING POWER OF SUPPLIERS    66
5.6.3    BARGAINING POWER OF BUYERS    66
5.6.4    THREAT OF SUBSTITUTES    66
5.6.5    THREAT OF NEW ENTRANTS    67
5.7    REGULATORY ANALYSIS    67
5.7.1    NORTH AMERICA    67
5.7.1.1    US    67
TABLE 10    US FDA: MEDICAL DEVICE CLASSIFICATION    67
TABLE 11    US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS    68
5.7.1.2    Canada    68
TABLE 12    CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS    68
FIGURE 30    CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS    69
5.7.2    EUROPE    69
FIGURE 31    EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES    69
5.7.3    ASIA PACIFIC    70
5.7.3.1    Japan    70
TABLE 13    JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA    70
5.7.3.2    China    71
TABLE 14    CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL    71
TABLE 15    CHINA: CLASSIFICATION OF MEDICAL DEVICES    71
5.7.3.3    India    71
5.8    IMPACT OF COVID-19 ON THE INJECTION PENS MARKET    72
5.9    PATENT ANALYSIS    72
5.9.1    PATENT PUBLICATION TRENDS FOR INJECTION PENS    72
FIGURE 32    PATENT PUBLICATION TRENDS (JANUARY 2011–SEPTEMBER 2021)    73
5.9.2    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS    73
FIGURE 33    TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR
INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)    74
FIGURE 34    TOP APPLICANT COUNTRIES/REGIONS FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)    75
5.10    TECHNOLOGY ANALYSIS    75
TABLE 16    PEN INJECTORS CLASSIFICATION    75
5.10.1    KEY TECHNOLOGIES    76
5.10.1.1    Dose setting and needle actuation    76
5.10.1.2    Pen injector material    76
5.10.2    COMPLEMENTARY TECHNOLOGIES    76
5.10.2.1    In-built dose and time log    76
5.10.2.2    Wireless connectivity    76
5.10.2.3    Smartpen injectors    77
5.10.2.4    Smart caps and attachments    77
5.10.2.5    Injector temperature monitoring    77
5.10.3    ADJACENT TECHNOLOGIES    78
5.10.3.1    Autoinjectors    78
5.10.3.2    Insulin pumps    78
6    INJECTION PENS MARKET, BY TYPE    79
6.1    INTRODUCTION    80
TABLE 17    INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    80
6.2    DISPOSABLE INJECTION PENS    80
6.2.1    HIGH PATIENT COMPLIANCE AND EASE OF HANDLING TO DRIVE
THE ADOPTION OF DISPOSABLE INJECTION PENS    80
TABLE 18    DISPOSABLE INJECTION PENS AVAILABLE IN THE MARKET    81
TABLE 19    DISPOSABLE INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    81
6.3    REUSABLE INJECTION PENS    82
6.3.1    REUSABLE INJECTION PENS TO REGISTER THE HIGHEST GROWTH
DUE TO TECHNOLOGICAL ADVANCEMENTS    82
TABLE 20    REUSABLE INJECTION PENS AVAILABLE IN THE MARKET    82
TABLE 21    REUSABLE INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    83
7    INJECTION PENS MARKET, BY THERAPY    84
7.1    INTRODUCTION    85
TABLE 22    INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    85
7.2    DIABETES    85
TABLE 23    INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    86
TABLE 24    INJECTION PENS MARKET FOR DIABETES THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)    86
7.2.1    INSULIN    87
7.2.1.1    Rising prevalence of diabetes is driving the growth of this market    87
TABLE 25    EXAMPLES OF INSULIN INJECTION PENS    88
TABLE 26    INJECTION PENS MARKET FOR INSULIN THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)    88
7.2.2    GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY    89
7.2.2.1    Strong focus of major pharmaceutical companies to introduce
GLP-1 drugs to drive market growth    89
TABLE 27    EXAMPLES OF GLP-1 INJECTION PENS    89
TABLE 28    INJECTION PENS MARKET FOR GLP-1 THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)    90
7.3    GROWTH HORMONE THERAPY    90
7.3.1    DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN
THE MARKET GROWTH    90
TABLE 29    EXAMPLES OF INJECTION PENS FOR GROWTH HORMONE THERAPY    91
TABLE 30    INJECTION PENS MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)    92
7.4    OSTEOPOROSIS    92
7.4.1    GROWING PREVALENCE OF OSTEOPOROSIS IN GERIATRIC PATIENTS AND WOMEN TO DRIVE MARKET GROWTH    92
TABLE 31    EXAMPLES OF INJECTION PENS FOR OSTEOPOROSIS THERAPY    93
TABLE 32    INJECTION PENS MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)    94
7.5    FERTILITY    94
7.5.1    DECREASE IN FERTILITY RATE HAS RESULTED IN THE INCREASED
USE OF INJECTION PENS    94
TABLE 33    EXAMPLES OF INJECTION PENS FOR FERTILITY THERAPY    95
TABLE 34    INJECTION PENS MARKET FOR FERTILITY THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)    95
7.6    CANCER    96
7.6.1    RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH    96
TABLE 35    EXAMPLES OF INJECTION PENS FOR CANCER THERAPY    96
TABLE 36    INJECTION PENS MARKET FOR CANCER THERAPY, BY COUNTRY,
2019–2026 (USD MILLION)    97
7.7    AUTOIMMUNE DISEASES    97
7.7.1    DEVELOPMENTS IN THERAPIES AND DELIVERY DEVICES FOR THE TREATMENT OF MS TO BOOST THE MARKET GROWTH    97
TABLE 37    EXAMPLES OF INJECTION PENS FOR MULTIPLE SCLEROSIS AND
PSORIASIS THERAPY    98
TABLE 38    INJECTION PENS MARKET FOR AUTOIMMUNE DISEASE THERAPY,
BY COUNTRY, 2019–2026 (USD MILLION)    98
7.8    OTHER THERAPIES    99
TABLE 39    INJECTION PENS MARKET FOR OTHER THERAPIES, BY COUNTRY,
2019–2026 (USD MILLION)    99
8    INJECTION PENS MARKET, BY END USER    100
8.1    INTRODUCTION    101
TABLE 40    INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    101
8.2    HOME CARE SETTINGS    101
8.2.1    HOME CARE SETTINGS ARE THE LARGEST END USERS OF INJECTION PENS    101
TABLE 41    INJECTION PENS MARKET FOR HOME CARE SETTINGS, BY COUNTRY,
2019–2026 (USD MILLION)    102
8.3    HOSPITALS & CLINICS    103
8.3.1    GROWING INCIDENCE OF NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES HAVE INCREASED THE DEMAND FOR INJECTION PENS    103
TABLE 42    INJECTION PENS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,
2019–2026 (USD MILLION)    104
9    INJECTION PENS MARKET, BY REGION    105
9.1    INTRODUCTION    106
TABLE 43    INJECTION PENS MARKET, BY REGION, 2019–2026 (USD MILLION)    106
FIGURE 35    EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH
IN THE FORECAST PERIOD    107
9.2    NORTH AMERICA    107
FIGURE 36    NORTH AMERICA: INJECTION PENS MARKET SNAPSHOT    108
TABLE 44    INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    108
TABLE 45    NORTH AMERICA: INJECTION PENS MARKET, BY TYPE,
2019–2026 (USD MILLION)    109
TABLE 46    NORTH AMERICA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    109
TABLE 47    NORTH AMERICA: INJECTION PENS MARKET FOR DIABETES THERAPY,
BY TYPE, 2019–2026 (USD MILLION)    109
TABLE 48    NORTH AMERICA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    110
9.2.1    US    110
9.2.1.1    The US dominates the North American injection pens market    110
FIGURE 37    TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020)    110
TABLE 49    US: KEY MACROINDICATORS    111
TABLE 50    US: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    112
TABLE 51    US: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    112
TABLE 52    US: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    112
TABLE 53    US: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    113
9.2.2    CANADA    113
9.2.2.1    Unfavorable regulatory processes in Canada to restrain
the market growth    113
TABLE 54    CANADA: KEY MACROINDICATORS    114
TABLE 55    CANADA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    114
TABLE 56    CANADA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    115
TABLE 57    CANADA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    115
TABLE 58    CANADA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    115
9.3    EUROPE    116
TABLE 59    EUROPE: INJECTION PENS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)    116
TABLE 60    EUROPE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    117
TABLE 61    EUROPE: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    117
TABLE 62    EUROPE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    117
TABLE 63    EUROPE: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    118
9.3.1    GERMANY    118
9.3.1.1    High diabetes expenditure and reimbursement for injection pens to drive the market in Germany    118
TABLE 64    GERMANY: KEY MACROINDICATORS    119
TABLE 65    GERMANY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    119
TABLE 66    GERMANY: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    120
TABLE 67    GERMANY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)    120
TABLE 68    GERMANY: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    120
9.3.2    FRANCE    121
9.3.2.1    Misuse of injection pens pose a threat to the growth of this market    121
TABLE 69    FRANCE: KEY MACROINDICATORS    121
TABLE 70    FRANCE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    122
TABLE 71    FRANCE: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    122
TABLE 72    FRANCE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    122
TABLE 73    FRANCE: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    123
9.3.3    UK    123
9.3.3.1    NHS support and access to cost-effective injection pens are likely to drive the market in the UK    123
TABLE 74    UK: KEY MACROINDICATORS    124
TABLE 75    UK: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    124
TABLE 76    UK: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    125
TABLE 77    UK: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    125
TABLE 78    UK: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    125
9.3.4    ITALY    126
9.3.4.1    Regional variation in terms of coverage and benefits to hinder the market growth    126
TABLE 79    ITALY: KEY MACROINDICATORS    126
TABLE 80    ITALY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    127
TABLE 81    ITALY: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    127
TABLE 82    ITALY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    127
TABLE 83    ITALY: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    128
9.3.5    SPAIN    128
9.3.5.1    Supportive regulations mandating the use of safety injection pens to boost the growth of the Spanish market    128
TABLE 84    SPAIN: KEY MACROINDICATORS    129
TABLE 85    SPAIN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    129
TABLE 86    SPAIN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    130
TABLE 87    SPAIN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    130
TABLE 88    SPAIN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    130
9.3.6    BENELUX    131
9.3.6.1    Increasing awareness about injection pen devices to
drive market growth    131
TABLE 89    BENELUX: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    131
TABLE 90    BENELUX: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    132
TABLE 91    BENELUX: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)    132
TABLE 92    BENELUX: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    132
9.3.7    REST OF EUROPE    133
TABLE 93    ROE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    133
TABLE 94    ROE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    134
TABLE 95    ROE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    134
TABLE 96    ROE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    134
9.4    ASIA PACIFIC    135
FIGURE 38    ASIA PACIFIC: INJECTION PENS MARKET SNAPSHOT    136
TABLE 97    APAC: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    137
TABLE 98    APAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    137
TABLE 99    APAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    137
TABLE 100    APAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    138
TABLE 101    APAC: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    138
9.4.1    JAPAN    138
9.4.1.1    High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan    138
TABLE 102    JAPAN: KEY MACROINDICATORS    139
TABLE 103    JAPAN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    139
TABLE 104    JAPAN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    140
TABLE 105    JAPAN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    140
TABLE 106    JAPAN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    140
9.4.2    CHINA    141
9.4.2.1    Large patient population and healthcare infrastructure improvements to drive the market growth in China    141
TABLE 107    CHINA: KEY MACROINDICATORS    141
TABLE 108    CHINA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    142
TABLE 109    CHINA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    142
TABLE 110    CHINA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    142
TABLE 111    CHINA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    143
9.4.3    INDIA    143
9.4.3.1    Rising prevalence of obesity to drive market growth    143
TABLE 112    INDIA: KEY MACROINDICATORS    144
TABLE 113    INDIA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    144
TABLE 114    INDIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    145
TABLE 115    INDIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    145
TABLE 116    INDIA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    145
9.4.4    SOUTHEAST ASIA    146
9.4.4.1    Growing awareness about diabetes to drive the adoption of
injection pens    146
FIGURE 39    DIABETES PREVALENCE IN SOUTHEAST ASIA (2019)    146
FIGURE 40    HEALTHCARE EXPENDITURE (% OF GDP) IN SOUTHEAST ASIA (2018)    147
FIGURE 41    GERIATRIC POPULATION (% OF THE TOTAL POPULATION), 2019    147
TABLE 117    SOUTHEAST ASIA: INJECTION PENS MARKET, BY TYPE,
2019–2026 (USD MILLION)    147
TABLE 118    SOUTHEAST ASIA: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    148
TABLE 119    SOUTHEAST ASIA: INJECTION PENS MARKET FOR DIABETES THERAPY,
BY TYPE, 2019–2026 (USD MILLION)    148
TABLE 120    SOUTHEAST ASIA: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    148
9.4.5    REST OF APAC    149
TABLE 121    ROAPAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    149
TABLE 122    ROAPAC: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    149
TABLE 123    ROAPAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    150
TABLE 124    ROAPAC: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    150
9.5    LATIN AMERICA    150
TABLE 125    LATAM: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)    151
TABLE 126    LATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    151
TABLE 127    LATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    151
TABLE 128    LATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    152
TABLE 129    LATAM: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    152
9.5.1    BRAZIL    152
9.5.1.1    Brazil dominates the injection pens market in Latin America    152
TABLE 130    BRAZIL: KEY MACROINDICATORS    153
TABLE 131    BRAZIL: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    153
TABLE 132    BRAZIL: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    154
TABLE 133    BRAZIL: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    154
TABLE 134    BRAZIL: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    154
9.5.2    MEXICO    155
9.5.2.1    Increasing incidence of lifestyle-related disorders to drive
market growth in Mexico    155
TABLE 135    MEXICO: KEY MACROINDICATORS    155
TABLE 136    MEXICO: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    156
TABLE 137    MEXICO: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    156
TABLE 138    MEXICO: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    156
TABLE 139    MEXICO: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    157
9.5.3    REST OF LATIN AMERICA    157
FIGURE 42    HEALTH EXPENDITURE (% OF GDP) IN LATIN AMERICAN COUNTRIES, 2018    157
TABLE 140    ROLATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    158
TABLE 141    ROLATAM: INJECTION PENS MARKET, BY THERAPY,
2019–2026 (USD MILLION)    158
TABLE 142    ROLATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION)    158
TABLE 143    ROLATAM: INJECTION PENS MARKET, BY END USER,
2019–2026 (USD MILLION)    159
9.6    MIDDLE EAST & AFRICA    159
9.6.1    INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY TO
SUPPORT MARKET GROWTH    159
TABLE 144    MEA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION)    160
TABLE 145    MEA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION)    160
TABLE 146    MEA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE,
2019–2026 (USD MILLION)    160
TABLE 147    MEA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION)    161
10    COMPETITIVE LANDSCAPE    162
10.1    OVERVIEW    162
10.2    KEY PLAYER STRATEGIES    162
10.3    REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS    163
FIGURE 43    REVENUE ANALYSIS OF THE TOP PLAYERS IN THE INJECTION PENS MARKET    163
10.4    MARKET SHARE ANALYSIS    164
FIGURE 44    INJECTION PENS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020    164
10.5    MARKET RANKING ANALYSIS OF OEM COMPANIES    165
FIGURE 45    INJECTION PENS MARKET RANKING, BY OEM COMPANY (2020)    165
10.6    COMPANY EVALUATION QUADRANT    166
10.6.1    STARS    166
10.6.2    EMERGING LEADERS    166
10.6.3    PERVASIVE PLAYERS    166
10.6.4    PARTICIPANTS    166
FIGURE 46    INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT (2020)    167
10.7    COMPANY EVALUATION QUADRANT FOR START-UPS    168
10.7.1    PROGRESSIVE COMPANIES    168
10.7.2    DYNAMIC COMPANIES    168
10.7.3    STARTING BLOCKS    168
10.7.4    RESPONSIVE COMPANIES    168
FIGURE 47    INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS (2020)    169
10.8    COMPANY PRODUCT FOOTPRINT    170
TABLE 148    PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY TYPE    170
TABLE 149    PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY THERAPY    171
10.9    GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE INJECTION PENS MARKET    173
TABLE 150    GEOGRAPHIC REVENUE MIX: INJECTION PENS MARKET (2020)    173
10.10    COMPETITIVE SCENARIO    174
10.10.1    PRODUCT LAUNCHES    174
TABLE 151    PRODUCT LAUNCHES (JANUARY 2018–SEPTEMBER 2021)    174
10.10.2    OTHER DEVELOPMENTS    175
TABLE 152    OTHER DEVELOPMENTS (JANUARY 2018–SEPTEMBER 2021)    175

11    COMPANY PROFILES    176
11.1    KEY PLAYERS    176
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1.1    NOVO NORDISK A/S    176
TABLE 153    NOVO NORDISK A/S: BUSINESS OVERVIEW    176
FIGURE 48    NOVO NORDISK A/S: COMPANY SNAPSHOT (2020)    177
11.1.2    BECTON, DICKINSON AND COMPANY    179
TABLE 154    BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW    179
FIGURE 49    BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)    180
11.1.3    YPSOMED HOLDING AG    182
TABLE 155    YPSOMED HOLDING AG: BUSINESS OVERVIEW    182
FIGURE 50    YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020)    183
11.1.4    SANOFI    185
TABLE 156    SANOFI: BUSINESS OVERVIEW    185
FIGURE 51    SANOFI: COMPANY SNAPSHOT (2020)    186
11.1.5    ELI LILLY AND COMPANY    188
TABLE 157    ELI LILLY AND COMPANY: BUSINESS OVERVIEW    188
FIGURE 52    ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)    189
11.1.6    MERCK KGAA    191
TABLE 158    MERCK KGAA: BUSINESS OVERVIEW    191
FIGURE 53    MERCK KGAA: COMPANY SNAPSHOT (2020)    192
11.1.7    ASTRAZENECA    193
TABLE 159    ASTRAZENECA: BUSINESS OVERVIEW    193
FIGURE 54    ASTRAZENECA: COMPANY SNAPSHOT (2020)    194
11.1.8    F. HOFFMANN-LA ROCHE LTD.    196
TABLE 160    F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW    196
FIGURE 55    F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)    197
11.1.9    OWEN MUMFORD    198
TABLE 161    OWEN MUMFORD: BUSINESS OVERVIEW    198
11.1.10    SULZER LTD.    199
TABLE 162    SULZER LTD.: BUSINESS OVERVIEW    199
11.1.11    SUN PHARMACEUTICAL INDUSTRIES LTD.    200
TABLE 163    SUN PHARMACEUTICAL INDUSTRIES LTD: BUSINESS OVERVIEW    200
FIGURE 56    SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)    201
11.1.12    PFIZER    202
TABLE 164    PFIZER: BUSINESS OVERVIEW    202
FIGURE 57    PFIZER: COMPANY SNAPSHOT (2020)    203
11.1.13    BIOCON LTD.    204
TABLE 165    BIOCON LTD.: BUSINESS OVERVIEW    204
FIGURE 58    BIOCON LTD.: COMPANY SNAPSHOT (2020)    205

11.1.14    LUPIN LTD.    206
TABLE 166    LUPIN LTD.: BUSINESS OVERVIEW    206
FIGURE 59    LUPIN LTD.: COMPANY SNAPSHOT (2020)    207
11.1.15    WOCKHARDT LTD.    208
TABLE 167    WOCKHARDT LTD.: BUSINESS OVERVIEW    208
FIGURE 60    WOCKHARDT LTD.: COMPANY SNAPSHOT (2020)    208
11.1.16    APTARGROUP, INC.    210
TABLE 168    APTARGROUP, INC.: BUSINESS OVERVIEW    210
FIGURE 61    APTARGROUP, INC.: COMPANY SNAPSHOT (2020)    211
11.1.17    NOVARTIS AG    212
TABLE 169    NOVARTIS AG: BUSINESS OVERVIEW    212
FIGURE 62    NOVARTIS AG: COMPANY SNAPSHOT (2020)    213
11.1.18    GERRESHEIMER AG    214
TABLE 170    GERRESHEIMER AG: BUSINESS OVERVIEW    214
FIGURE 63    GERRESHEIMER AG: COMPANY SNAPSHOT (2020)    215
11.2    OTHER PLAYERS    216
11.2.1    SHAILY ENGINEERING PLASTICS LTD.    216
TABLE 171    SHAILY ENGINEERING PLASTICS LTD.: BUSINESS OVERVIEW    216
11.2.2    BESPAK EUROPE LTD.    217
TABLE 172    BESPAK EUROPE LTD.: BUSINESS OVERVIEW    217
11.2.3    SHL MEDICAL AG    218
TABLE 173    SHL MEDICAL AG: BUSINESS OVERVIEW    218
11.2.4    EMPERRA GMBH    219
TABLE 174    EMPERRA GMBH: BUSINESS OVERVIEW    219
11.2.5    NEMERA FRANCE SAS    220
TABLE 175    NEMERA FRANCE SAS: BUSINESS OVERVIEW    220
11.2.6    COMPANION MEDICAL, INC.    221
TABLE 176    COMPANION MEDICAL, INC.: BUSINESS OVERVIEW    221
11.2.7    JIANGSU DELFU MEDICAL DEVICE CO., LTD.    222
TABLE 177    JIANGSU DELFU MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW    222
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12    APPENDIX    223
12.1    DISCUSSION GUIDE    223
12.2    KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    227
12.3    AVAILABLE CUSTOMIZATIONS    229
12.4    RELATED REPORTS    229
12.5    AUTHOR DETAILS    231"